How AstraZeneca Is Playing Its Cancer Cards To Become An $80 ... Japan, the U.K. and the U.S. each year, Dave Fredrickson, executive vice president of AstraZeneca's oncology business unit, ...

AstraZeneca is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as ...

We expect AstraZeneca AZN to beat expectations when it reports second-quarter 2023 results on Jul 28. In the last reported quarter, the company delivered an earnings surprise of 11.63%.

AstraZeneca is considering moving its stock market listing from London, where it is the exchange's most valuable company, to ...

AstraZeneca's New-York listed ADR rose 2.6% shortly after the open; shares in the drugmaker sold off Monday after it reported mixed results in a trial for an experimental cancer drug.

AstraZeneca AZN will report fourth-quarter and full-year 2022 results on Feb 9. In the last reported quarter, ... What's in the Cards? February 07, 2023 — 10:26 am EST.